Bortezomib as a potential treatment for prostate cancer.
about
Ubiquitin-proteasome system involvement in Huntington's diseaseThe Importance of Ubiquitin E3 Ligases, SCF and APC/C, in Human CancersThe 26S proteasome is a multifaceted target for anti-cancer therapiesBoron chemicals in diagnosis and therapeuticsDiscovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cellsNatural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaBApigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.The 26S proteasome complex: an attractive target for cancer therapyProstate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.Bortezomib inhibits cell proliferation in prostate cancer.The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy.Targeted therapies for prostate cancer.EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanismHeat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells.Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistanceProline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1.Broad targeting of resistance to apoptosis in cancer.Safety of purified isoflavones in men with clinically localized prostate cancerInhibition of Akt pathways in the treatment of prostate cancer.Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IkappaBalpha.Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagyThe role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approachCelastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer.Future developments in the management of malignant pleural mesothelioma.Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines.Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity.Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells.Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse.E6AP promotes prostate cancer by reducing p27 expressionOvercoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.
P2860
Q21129327-D2EB7234-2584-44A2-8F93-64451FEE6692Q26777305-946E806F-5407-4E53-BEFD-47C0E188E30AQ26795764-C1597108-B9C0-4132-8474-2EC2F1438018Q27006075-5EEDFB34-B7BC-4D79-A3CE-2F66E33B0ABEQ33453188-FC1D522A-964B-44EC-995A-265EEFFF56A1Q33775541-253761EB-FB3B-40A4-B576-C2472E012AC5Q34448480-05D17542-2905-4247-9F52-C69D8C118BC4Q35624079-341AF874-3621-4E5F-BE34-B23CB079FA7BQ35823852-0D7AB790-E5DB-4A33-BA60-22F9B14CDD43Q35943077-F47AE6E1-E2F3-4E2E-9968-B6149A76AC73Q36066214-793F48DF-DA3D-48DC-BA5A-BB0EED881ED7Q36150842-7E04FAAF-0C77-4AF2-89AD-59557DCC871BQ36168253-3C3A0F2C-F63F-4F96-A887-743C3934EAFCQ36187025-23935D29-C78E-4F62-A0E5-337AC6F46CF6Q36233076-C1997D96-1186-457C-8FB7-77741F1464FAQ36282200-BE8A23EF-75C1-4349-99F1-E11CD3FEEF46Q36332904-004E4894-8F44-4A54-B791-E0D9EA4981C6Q36483749-CD04716C-4578-4732-A00B-692A4A88430DQ36741928-3C300D37-6A47-49A6-9E19-2C1330750C5EQ36807494-006F7C83-9A99-4B06-9685-7F3580038E9CQ36825684-B3359C5F-3E88-4510-8CCB-6A8FCE0B98F6Q36953274-35A45351-F331-4771-A0A9-E5FDBBDE258AQ37263062-8E79F3AB-B62B-48F4-9550-ED5F85BA833FQ37337735-EDB48EFF-95B2-46F5-B699-A35AEB7C9B23Q37349650-75FC1F71-A485-4531-9B58-C2D76431B3E7Q37449036-B977EF63-91F2-4D41-9134-44F0F1490B1BQ37560404-C55E3C16-E6A3-4EDD-904A-EADA1D69F0E2Q37727613-3A2DDABF-126B-4B3B-A27B-FABBAD751BC6Q38739821-C48D98AC-1A5B-4094-A453-7CD18A1A193AQ38745588-A5FE05AF-8BCB-4246-83BB-FDA7AB81AE5BQ39119033-6AC39207-CA49-4876-BB7E-106692CFCEB2Q39398243-3D2743F1-9291-4FFA-91C9-46592BA8629DQ39475750-2E56870F-823C-4505-AE19-2141B4C7EBE3Q39748970-0D36497A-1F41-4C22-B94F-9DDD2A81659EQ39916485-D404C5DD-C935-4EEF-96F0-B4A358EA435EQ39926659-1BB17E93-7CD3-40CE-81FB-9461E7F3B159Q39990380-07F78330-7E53-4410-9EEF-B77CD9B2C2D6Q42022163-99E4CCF1-8A14-49E9-88EA-0D49500343E1Q42335715-DB2349FB-5061-41EC-84C7-2690CD57900EQ42632400-43456625-2C1C-4817-9162-1AB486278FAA
P2860
Bortezomib as a potential treatment for prostate cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Bortezomib as a potential treatment for prostate cancer.
@ast
Bortezomib as a potential treatment for prostate cancer.
@en
type
label
Bortezomib as a potential treatment for prostate cancer.
@ast
Bortezomib as a potential treatment for prostate cancer.
@en
prefLabel
Bortezomib as a potential treatment for prostate cancer.
@ast
Bortezomib as a potential treatment for prostate cancer.
@en
P1433
P1476
Bortezomib as a potential treatment for prostate cancer.
@en
P2093
Christopher J Logothetis
Christos N Papandreou
P304
P356
10.1158/0008-5472.CAN-03-2707
P407
P577
2004-08-01T00:00:00Z